290 related articles for article (PubMed ID: 25381972)
1. Monoclonal gammopathy of undetermined significance in patients with psoriasis: is it really a side effect of biological therapy?
Conti A; Esposito I; Lasagni C; Miglietta R; Padalino C; Fabiano A; Pellacani G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S35-7. PubMed ID: 25381972
[TBL] [Abstract][Full Text] [Related]
2. Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.
Prignano F; Pescitelli L; Ricceri F; Ermini A; Lotti T
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1444-8. PubMed ID: 21834947
[TBL] [Abstract][Full Text] [Related]
3. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
[No Abstract] [Full Text] [Related]
4. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with psoriasis treated with biological drugs needing a surgical treatment.
Fabiano A; De Simone C; Gisondi P; Piaserico S; Lasagni C; Pellacani G; Conti A
Drug Dev Res; 2014 Nov; 75 Suppl 1():S24-6. PubMed ID: 25381969
[TBL] [Abstract][Full Text] [Related]
6. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
7. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
8. Viewpoint on handling anti-TNF failure in psoriasis.
Bracke S; Lambert J
Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
[TBL] [Abstract][Full Text] [Related]
9. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
10. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
12. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
13. Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA; Lipozencić J
Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
[TBL] [Abstract][Full Text] [Related]
14. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
17. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
[No Abstract] [Full Text] [Related]
18. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
19. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
20. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]